Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Retapamulin

Classification: A

Drug products: Altargo®

ATC code: D06AX13

Substances: retapamulin

Summary

The efficacy of retapamulin in treatment of skin infections is similar in men and women. However, studies of dosing and adverse events with a relevant gender analysis are scarce.
 
In our opinion, the present evidence does not motivate differentiation in dosing or treatment between men and women.

Additional information

Pharmacokinetics an dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of retapamulin have been found.

Effects

The efficacy of topical retapamulin in patients with secondarily infected traumatic lesions was evaluated in a randomized, double-blind, placebo-controlled study (219 men, 140 women; all ages >2 months). Men/boys and women/girls receiving retapamulin had similar success rates, measured as clinical improvement [1]. Also, the original manufacturer report similar responses to retapamulin in treatment of impetigo in both sexes in clinical studies [2, 3].

Adverse effects

Clinical trials of retapamulin safety have not reported sex-stratified results [1, 4].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2016-03-29

References

  1. Tomayko JF, Li G, Breton JJ, Scangarella-Oman N, Dalessandro M, Martin M. The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. Adv Skin Wound Care. 2013;26:113-21. PubMed
  2. ALTABAX ( retapamulin). DailyMed [www]. US National Library of Medicine. [updated 2015-04-20, cited 2016-03-29]. länk
  3. ALTABAX ( retapamulin). Labeling. U.S. Food and Drug Administration (FDA); 2012.
  4. Koning S, van der Wouden JC, Chosidow O, Twynholm M, Singh KP, Scangarella N et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158:1077-82. PubMed
  5. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-05-30.] Socialstyrelsens statistikdatabas

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson